Cytokine‐producing B‐cell balance associates with skin fibrosis in patients with systemic sclerosis

Motoki Horii,Natsumi Fushida,Tomoyuki Ikeda,Kyosuke Oishi,Yasuhito Hamaguchi,Yuichi Ikawa,Akito Komuro,Takashi Matsushita
DOI: https://doi.org/10.1111/1346-8138.16495
2022-06-27
Abstract:Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and lung fibrosis. Over 90% of patients with SSc are positive for autoantibodies. In addition, the serum levels of B‐cell activating factor, a potent B‐cell stimulator, are correlated with SSc severity and activity. Thus, B cells play an important role in SSc pathogenesis. However, two opposing B‐cell subsets exist: effector B cells (Beff) and regulatory B cells (Breg). Interleukin (IL)‐6‐producing Beff have been shown to promote scleroderma in a mouse model, whereas IL‐10‐producing Breg inhibit scleroderma development. In the present study, we investigated the clinical association of effector and regulatory B cells in patients with SSc. The blood levels of IL‐6‐producing Beff and IL‐10‐producing Breg were measured in 30 patients with SSc and 21 healthy subjects by flow cytometry. The frequency of IL‐6‐producing Beff in the blood was significantly (p
dermatology
What problem does this paper attempt to address?